SOLAR-PROMOTION
28.5.2024 10:42:32 CEST | Business Wire | Press release
Visitors to The smarter E Europe, Europe’s Largest Alliance of Exhibitions for the Energy Industry, will find out how private consumers can become self-sufficient in electricity, heat and transport in a smart way and how this creates new business opportunities for installers and system providers. The smarter E Europe combines the four trade fairs Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe and takes place from June 19 to 21 at Messe München. Around 3,000 exhibitors and more than 115,000 visitors from all over the world are expected in 19 exhibition halls and on an outdoor area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528827105/en/
The smarter E Europe shows interplay of components. ©Solar Promotion GmbH
There are around 19.3 million residential buildings in Germany. More than half of these will need to be renovated and equipped with photovoltaics over the next 20 years. But residential buildings also play a central role in solar expansion throughout Europe. Everywhere, solar systems are being installed with storage systems, as this allows the solar power generated to be used as needed.
Increasing electrification in the transport and heating sectors
Solar power has been generated and stored to supply the home, but what else can it be used for? For the increasingly popular electric car. In the home system, battery electric vehicles as well as heat pumps can be charged and operated cost-effectively and climate-neutrally with the solar power. In Germany, 51 percent more heat pumps were sold last year than in 2022. With the adoption of the EU Heat Pump Action Plan, this development will continue dynamically. The combination of PV, a storage system, electric car and heat pump forms an effective network of electricity-generating, electricity-storing and electricity-consuming units.
An interplay of components and trade disciplines
The industry offers a wide range of components - from PV systems and intelligent wall boxes to smart meters and much more. However, successfully building a comprehensive energy system requires not only interaction between the individual components, but also smooth cooperation between the electrical trade, plumbing, heating and air conditioning technology (HVAC) and other trades.
Optimize self-consumption, relieve the grid
The electricity system requires a high degree of flexibility in order to be able to provide a renewable energy supply 24/7. Flexible small consumers with their own home energy systems can make a major contribution to keeping electricity generation and consumption in balance while optimizing their own consumption at low cost.
Dynamic electricity tariffs: Supply meets demand
Dynamic electricity tariffs are another way of better coordinating supply and demand. Consumers base their consumption on the current electricity prices, which change depending on supply and demand. From 2025, all electricity suppliers in Germany will be obliged to offer their customers a dynamic electricity tariff. Prerequisite for this is the installation of a smart meter.
The smarter E Europe
"Accelerating Integrated Energy Solutions" - under this motto, The smarter E Europe, Europe's largest trade fair alliance for the energy industry, focuses on cross-industry solutions for a 24/7 renewable energy supply in the electricity, heating and transport sectors. The smarter E Europe combines four trade fairs and will take place from June 19-21, 2024 at Messe München.
Further information: www.TheSmarterE.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528827105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom